32 results about "Lymphocyte infiltration" patented technology

The present invention relates to a humanized immunoglobulin that has binding specificity for α4β7 integrin and comprises the complementarity determining regions (CDRs) of mouse Act-1 antibody, and to the humanized light chain of the humanized immunoglobulin. The present invention further relates to a humanized immunoglobulin light chain. The invention also relates to isolated nucleic acids, recombinant vectors and host cells that comprise a sequence which encodes a humanized immunoglobulin or immunoglobulin light chain, and to a method of preparing a humanized immunoglobulin. The humanized immunoglobulins can be used in therapeutic applications, for example to control lymphocyte infiltration to mucosal tissue or to treat inflammatory bowel disease.

An objective of the present invention is to provide a safe and effective vaccine therapy for Alzheimer's disease. A minus strand RNA viral vector carrying amyloid gene was constructed, and administered intranasally to 24- to 25-months-old APP transgenic mice. The level of serum anti-A 42 antibody was determined and showed to be markedly higher than the control. The results of histological investigation showed that the administration of a vector of the present invention markedly reduced senile plaques in all of the frontal lobe, parietal lobe, and hippocampus. The brain A level was also markedly reduced. Furthermore, the administration of a vector of the present invention did not result in lymphocyte infiltration in the central nervous system.

The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor.The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and / or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1 / PD- L1 monotherapy.

A medicament for preventive and / or therapeutic treatment of a secretory dysfunctional disease associated with lymphocyte infiltration into a gland such as type I diabetes or Sjogren's syndrome, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.

[Object] Provided is a compound which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient for an agent for preventing and / or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells.[Means for Solution] According to the present invention, a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action, and is useful particularly as an active ingredient of an agent for preventing and / or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells can be provided. The 2H-chromene compound and a derivative thereof which are the compounds of the present invention have an S1P1 agonist action, and can be used particularly for prevention and / or treatment of a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells.

The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage / lymphocyte infiltration in the kidney, etc.

The invention provides a new application of fingolimod and an analogue thereof in preparing medicines for treating cerebral infarction and further shows the mechanism of treatment, effective dose, suitable dosage form and the specific compound of the analogue. Experiments confirm that the fingolimod and the analogue thereof can relieve lymphocyte infiltration caused by cerebral infarction, the relieving effect can be taken as a new target for treating cerebral infraction, furthermore, based on the new properties of the fingolimod and the analogue thereof, the new application of the fingolimod and the analogue thereof in preparing medicines for treating cerebral infraction is confirmed. The clinical applicability of the fingolimod and the analogue thereof is enlarged, the fact that the immune cells involve in cerebral infarction pathological lesion is disclosed, and the medicine prepared by the fingolilmod and the analogue thereof has a remarkable curative effect on cerebral infraction injure, and has prosperous generalization prospect.

The invention discloses a pathological image classification method and system based on deep learning and machine learning, and the method mainly comprises the following steps: constructing a target detection network model based on the deep learning technology, obtaining the positions of lymphocytes in a pathological image, and carrying out the statistics of the infiltration focus number of the lymphocytes; extracting global spatial arrangement and distribution characteristics of lymphocytes on the basis, and quantifying the infiltration degree of the lymphocytes in the pathological image; andtraining a machine learning classifier to obtain a pathological image classification result. According to the method, an artificial intelligence technology is utilized, and accurate and automatic classification of pathological images with different lymphocyte infiltration degrees is realized through automatic detection of lymphocyte infiltration lesions and numeralization feature extraction of infiltration degrees.

The invention discloses applications of gene modified mesenchymal stem cell derived microvesicles in preparation of drugs for treating renal injury. Applications of mesenchymal stem cell derived and gene modified miR-34a-MSC-MV, which are specifically designed microvesicles, in preparation of drugs for treating renal injury are included. The level of miR-34a is detected by inducing the overexpression of the miR-34a in MSCs through lentiviral vectors. Through the discovery from pathological observation, the damage level of renal tissue can be obviously improved, renal interstitial fibrosis, lymphocyte infiltration and swelling and necrosis degrees of renal tubules can be obviously alleviated, and renal histopathological scores can be significantly reduced. Through in vivo and in vitro experiments, repair effects of MV and miR-34a-MV are verified; the effects of gene modified stem cells and paracrine products thereof are cleared; and an action mechanism is preliminarily discussed.

The invention discloses a pharmaceutical composition (a formula capable of strengthening body resistance and removing stasis) for treating hashimoto thyroiditis and a preparation method thereof. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 10 to 20 parts of radix ginseng, 30 to 45 parts of radix astragali seu hedysari, 20 to 30 parts of radix et rhizoma salviae miltiorrhizae, 15 to 25 parts of liquorice root, 15 to 25 parts of white paeony root, 5 to 10 parts of dried tangerine peel and 5 to 10 parts of dried ginger. The pharmaceutical composition is prepared from raw materials which are both used as medicines and foods or can be used for health-care products, has no toxic side effect and has low cost. A drug effect test proves that the traditional Chinese medicine composition provided by the invention can be used for effectively repairing shapes of thyroid gland cells, reducing lymphocytes infiltration, remarkably reducing a thyroid autoantibody and a thyroid hormone level, reducing TNF-alpha (Tumor Necrosis Factor-alpha) and raising IL-10 and has a remarkable treatment effect on the hashimoto thyroiditis.

The invention provides a new use of fingolimod and its structural analog in the preparation of cerebral hemorrhage treatment medicines, and further clarifies a treatment mechanism, an effective dosage, a suitable dosage form, and a concrete compound referred to the structural analog. Experiments prove that fingolimod and its structural analog can alleviate lymphocyte infiltration caused by cerebral hemorrhage, and the above alleviation effect can be used as a new cerebral hemorrhage target in order to determine the new use of the fingolimod and its structural analog in the preparation of cerebral hemorrhage treatment medicines based on the above property of the fingolimod and its structural analog. The clinic adaptation disease of the fingolimod and its structural analog is enlarged, and the participation of immune cells in the pathological lesion of the cerebral hemorrhage is disclosed. The medicines prepared in the invention have a substantial curative effect on the cerebral hemorrhage, and have a protruding popularization prospect.

The invention relates to an application of gene mutation in predicting immunotherapy sensitivity of a lung cancer patient, in particular to application of PTPRD gene mutation in predicting immunotherapy sensitivity of a TP53 mutant lung cancer patient and application of a PTPRD gene mutation detection product in preparing a product for predicting sensitivity of the TP53 mutant lung cancer patient to immune checkpoint inhibitor therapy. The existence of PTPRD gene mutation is an indication that the TP53 mutant lung cancer patient is sensitive to immune checkpoint inhibitor therapy. According to the application, the PTRPD mutant gene is screened as a population biomarker for predicting ICI sensitivity in the TP53 mutant lung cancer patient; and through PTRPD mutation, the tumor lymphocyte infiltration and PD-L1 expression level of the TP53 mutant lung cancer patient can be predicted, then ICI sensitive populations are predicted, and more immunotherapy benefited populations are accurately screened.

The invention relates to a novel pharmaceutical application of apatinib or a pharmaceutically acceptable salt thereof, in particular to an application of apatinib or a pharmaceutically acceptable saltthereof in preparation of a medicine for treating malignant mesothelioma. The in-vitro test result shows that apatinib mesylate inhibits MPM cell proliferation and activity, affects the G2 / M phase ofthe MPM cell cycle process and remarkably inhibits MPM cell movement and migration; an in-vivo test result shows that the apatinib mesylate obviously reduces the ePCI score and has no influence on the body weight of nude mice. The apatinib has no histological toxicity to lung, spleen, kidney and gastrointestinal tract, only has focal lymphocyte infiltration in liver and myocardial tissues, and has an obvious effect of down-regulating NPM2 gene expression. The new application of apatinib or the pharmaceutically acceptable salt thereof provided by the invention provides an important theoreticalbasis for application of apatinib or the pharmaceutically acceptable salt thereof in treatment of malignant mesothelioma, widens the treatment range of the drug, and provides a new drug solution fortreatment of malignant mesothelioma.

The present invention proposes a radiomics-based biomarker for detecting the presence and the density of tumor infiltrating CD8 T-cells in a solid tumor without having to use any biopsy of said tumor. The invention also proposes to use this information to assess the immune phenotype of said solid tumor. In a particular embodiment, the invention proposes to prognose the survival and / or the treatment efficiency of cancer patients treated with immunotherapy such as anti-PD-1 / PD-L1 monotherapy.

The present invention relates to use of osthole for manufacturing a composition for treating focal segmental glomerulosclerosis (FSGS). Particularly, the present invention discloses that osthole is effective in treating focal segmental glomerulosclerosis (FSGS), which can alleviate various symptoms and signs of FSGS, including proteinuria, renal fibrosis, glomerular epithelial hyperplasia lesion (EPHL), and macrophage / lymphocyte infiltration in the kidney, etc.

The invention provides application of ribavirin in preparing a medicine for treating ischemic cerebral apoplexy. Upon experimental means, the ribavirin can achieve an effect on treating inflammations by relieving a lymphocytes infiltration phenomenon caused by the ischemic cerebral apoplexy, and subsequently a therapeutic effect can be achieved on the ischemic cerebral apoplexy. According to the invention, the clinical applicability of the ribavirin and structural analogues thereof is widened; and the internal principle that lymphocytes participate in the pathological damage of the ischemic cerebral apoplexy is revealed. The medicine disclosed by the invention, through oral administration, can significantly diminish the necrosis volume of brain tissue, reduce inflammatory exudation amount of intra-cerebral vessels and relieve an edema phenomenon of the brain tissue; and the medicine has a significant curative effect on the ischemic cerebral apoplexy and has an outstanding prospect of popularization.

Provided is a 2H-chromene compound or a derivative thereof which has an excellent S1P1 agonist action. The 2H-chromene compound or derivative is particularly useful for preventing and / or treating a disease induced by undesirable lymphocyte infiltration or a disease induced by abnormal proliferation or accumulation of cells.

The invention provides a novel application of fingolimod and structural analogue of fingolimod in preparing a drug for treating cerebral hemorrhage, and further determines a treatment mechanism, an active dose and an appropriate dosage form and a specific compound pointed by the structural analogue. The nature of the fingoliimod and the structural analogue of the fingolimod for alleviating lymphocytes infiltration caused by cerebral hemorrhage is made clear by virtue of experimental means, and the alleviation effect is ensured to be used as a novel target spot for treating the cerebral hemorrhage, so that the novel application of the fingolimod and the structural analogue of the fingolimod in preparing the drug for treating the cerebral hemorrhage is determined on the basis of the novel nature f the fingolimod and the structural analogue of the fingolimod. The novel application of the invention enlarges the clinical applicability of the fingolimod and the structural analogue of the fingolimod, and discloses the fact that the immune cells anticipate in the cerebral hemorrhage pathological lesion, and the drug prepared by the invention is significant in curative effect for the cerebral hemorrhage and has remarkable popularization prospect.

The invention discloses an application of Cbl-b protein in preparation of a product with a protective effect on lung injury induced by tobacco smoke. The product with a protective effect on lung injury induced by tobacco smoke is a medicine for promoting Cbl-b protein expression. The invention also discloses a medicine with the protective effect on lung injury induced by tobacco smoke, and the medicine is beneficial to protecting lung injury induced by tobacco smoke, slowing down the decline of lung function, reducing lung tissue macrophage and lymphocyte infiltration, relieving lung tissue inflammatory response, reducing the degree of emphysema; and slowing the epithelial-mesenchymal transition process of lung tissues.

The invention discloses a method for recognizing mouse intravascular and extravascular lymphocytes and application thereof. The method comprises the steps of intravenous injection of an anti-CD45 antibody, preparation of mononuclear cells, preparation of a flow sample, analysis of labeling conditions of intravascular and extravascular lymphocytes and the like. Compared with the prior art, the method has the following advantages that (1) multi-label detection of samples can be realized; (2) lymphocyte conditions of a plurality of organs can be simultaneously detected; (3) the experiment resultis reliable; (4) operation steps are simple, and consumed time is short; and (5) the method is very wide in application prospect, and can be used as a factor for judging disease prognosis according tothe severity of lymphocyte infiltration. Lymphocyte infiltration conditions can be analyzed and studied in association with disease or tumor typing, prediction of response of clinical therapy, and regulation and control of a certain link of disease progression.

The invention provides application of ribavirin in preparing a medicine for treating ischemic cerebral apoplexy. Upon experimental means, the ribavirin can achieve an effect on treating inflammations by relieving a lymphocytes infiltration phenomenon caused by the ischemic cerebral apoplexy, and subsequently a therapeutic effect can be achieved on the ischemic cerebral apoplexy. According to the invention, the clinical applicability of the ribavirin and structural analogues thereof is widened; and the internal principle that lymphocytes participate in the pathological damage of the ischemic cerebral apoplexy is revealed. The medicine disclosed by the invention, through oral administration, can significantly diminish the necrosis volume of brain tissue, reduce inflammatory exudation amount of intra-cerebral vessels and relieve an edema phenomenon of the brain tissue; and the medicine has a significant curative effect on the ischemic cerebral apoplexy and has an outstanding prospect of popularization.

The present invention relates to a new use of a cinnamaldehyde derivative of formula (I) for treating glomerulonephritis (GN). Particularly, the present invention discloses that the cinnamaldehyde derivative of formula (I) is effective in treating glomerulonephritis (GN), which can alleviate various symptoms and signs of GN, including reducing proteinuria, serum blood urea nitrogen (BUN), glomerular cell proliferation, and renal macrophage / lymphocyte infiltration, etc.

The invention relates to application of a ZC3H12b gene or protein and a method for establishing a hepatic disease animal model. According to the invention, a gene editing technology is utilized, the zc3h12b gene of oryzias latipes is knocked out in a targeted mode, the oryzias latipes with Zc3h12b protein product deficiency are established, all the oryzias latipes show different degrees of hepatobiliary duct hyperplasia and fusion, hepatocyte steatosis, fibrosis and other hepatic lesions, the obvious fatty liver appears along with the month-old growth, local cyst necrosis occurs, lymphocyte infiltration is obvious in the hepatic sinusoid, the number of macrophages is increased abnormally, positive cells of human tumor markers CK19, SMA and GPC3 are detected, and it is suggested that ZC3H12b can serve as a therapeutic target and a biomarker of intrahepatic biliary cystadenoma, intrahepatic biliary cystadenocarcinoma or the related fatty liver or liver cancer. The zc3h12b-deficient oryzias latipes can be used as an animal model for researching the intrahepatic biliary cystadenoma, the intrahepatic biliary cystadenocarcinoma or the lesion process of the intrahepatic biliary cystadenoma and the intrahepatic biliary cystadenocarcinoma.

In the invention, selecting MIP-1alpha as guide molecule, active segment DT390 of diphtheria toxin as toxin molecule, constructing eukaryon plasmid of MIP-1alpha-DT390 recombination immunotoxin, and expressing the product in transfection animal body. The experiments show: the recombination immunotoxin MIP-1alpha-DT390 has character to special attack and kill activated Th1 cell while no effect to Th2 and B cells. After curing by the product, the clinical symptom of EAE is released obviously; the pathological section shows that compared with un-cured group, in the cured group, the cerebellum and spinal demyelination lesions reduces, meninges and vein peripheral lymphocyte infiltration decreases.

In the invention, selecting MIP-1alpha as guide molecule, active segment DT390 of diphtheria toxin as toxin molecule, constructing eukaryon plasmid of MIP-1alpha-DT390 recombination immunotoxin, and expressing the product in transfection animal body. The experiments show: the recombination immunotoxin MIP-1alpha-DT390 has character to special attack and kill activated Th1 cell while no effect to Th2 and B cells. After curing by the product, the clinical symptom of EAE is released obviously; the pathological section shows that compared with un-cured group, in the cured group, the cerebellum and spinal demyelination lesions reduces, meninges and vein peripheral lymphocyte infiltration decreases.

The invention provides a cerebral arterial thrombosis treatment drug. Experiments verify that tenofovir disoproxil fumarate and structural analogues thereof have the effect of treating inflammation by means of relief by lymphocytes infiltration caused by cerebral arterial thrombosis, and further achieve the effect of treating cerebral arterial thrombosis. On the basis, added natural drugs further improve the curative effect level, and particularly the selected ingredients do not have direct treatment or regulating effect on the respective cerebral blood supply system and the cerebral arterial thrombosis on the existing medical perceive level. Under this condition, the applicants accidentally discover that the traditional Chinese medicine composition obtained by integration of the ingredients and optimal design of the dosage of the ingredients can effectively regulate the cardiovascular functions and promote cardiac blood supply to further achieve the effect of treating cerebral arterial thrombosis, and has the advantages of quickness in taking effect, no side effect and the like.

The invention relates to the technical field of medicines, in particular to the use of pyrazolopyrimidine derivatives in treating autoimmune thyroid diseases. The pyrazolopyrimidine derivatives of the present invention have a good therapeutic effect on autoimmune thyroid diseases, can significantly reduce the levels of thyroid hormones such as T3, T4, FT3, FT4 in serum, and significantly reduce the levels of antibodies TMAb and TGAb in serum, Effectively improve lymphocyte infiltration in thyroid tissue. The therapeutic effect of the pyrazolopyrimidine derivative of the present invention on autoimmune thyroid disease is equivalent to that of thyroxine or prednisone.

The invention provides the application of the CDK7 inhibitor in the preparation of medicine for ulcerative colitis or colon cancer. Through the research on the treatment of mice with experimental ulcerative colitis and the research on the treatment of mice with colon cancer related to experimental ulcerative colitis, the present invention found for the first time that CDK7 inhibitors, especially THZ2, can inhibit the bloody stools accompanied by ulcerative colitis Symptoms, and can reduce the symptoms of diarrhea associated with ulcerative colitis, can effectively treat ulcerative colitis and ulcerative colitis-related colon cancer, help patients reduce body fluid loss, effectively shorten the bloody stool cycle, relieve the severity of bloody stool and The severity of diarrhea can reduce the infiltration of lymphocytes in the colon, reduce the level of inflammation-related proteins, reduce the incidence of tumors, shorten the treatment cycle of patients, and improve the cure rate. its application value.

The embodiment of the invention discloses application of elemonic acid and solid dispersion thereof in preparation of a medicine for treating ulcerative colitis, and belongs to the technical field of medicines. Experiments prove that the elemonic acid can remarkably relieve clinical symptoms of mice with ulcerative colitis, remarkably reduce necrosis of colon tissues of the mice, remarkably relieve damage to colon tissue structures, relieve inflammatory response and reduce lymphocyte infiltration; the levels of TNF-alpha and IL-1beta in colon tissues are obviously reduced, and meanwhile, the expression of TNF-alpha in serum is obviously reduced. The elemonic acid can be used for increasing the expression of tight binding proteins Occludin and claudin-1, protecting intercellular connection and enhancing the resistance of intestinal mucosa barriers of mice to exogenous microorganisms. The elemonic acid provided by the invention can be prepared into a medicine which has a good effect and is used for treating and / or preventing ulcerative colitis, and the dissolution rate of the medicine can be increased by preparing the elemonic acid into the solid dispersion, so that the oral absorption rate of the elemonic acid is increased.